ARTICLE | Finance
LPs choose Europe
Why Charles River, Knight Therapeutics invested in Forbion's third fund
April 25, 2016 7:00 AM UTC
Charles River Laboratories International Inc. (NYSE:CRL) and Knight Therapeutics Inc. (TSX:GUD) invested in Forbion Capital Partner's third life sciences fund to gain access to the firm's largely European portfolio.
Forbion Capital Fund III (FCF III) closed this month at €183 million ($208.2 million). About 70% of FCF III will target European investments, with the rest earmarked for the U.S. and Canada. ...